Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Guided Posters


ea0056gp2 | Acromegaly | ECE2018

Retinal vessel abnormalities in acromegaly

Fuchtbauer Laila , Olsson Daniel S , Norrman Lise-Lott , Bengtsson Bengt-AEke , Hellstrom Ann , Johannsson Gudmundur

Growth hormone (GH) and insulin like growth factor 1 (IGF-I) modulate and stimulate angiogenesis and endothelial function. Excess of GH, as in acromegaly, is associated with cardiovascular morbidity and mortality, which is reversible after normalization of IGF-I and GH. Diabetes mellitus (DM) is a common comorbidity in acromegaly, but the prevalence of diabetes retinopathy in patients with acromegaly is unknown. Also, the roles of GH and IGF-I in diabetes retinopathy are not f...

ea0056gp3 | Acromegaly | ECE2018

An insight into the putative risk factors for IGF-1/GH dichotomy during follow-up for acromegaly

Seejore Khyatisha , Kyriakakis Nikolaos , Giannoudi Marilena , Lynch Julie , Orme Steve M , Barth Julian H , Murray Robert D

Background: Growth Hormone (GH) and insulin-like growth factor 1 (IGF-1) are the biomarkers used to assess disease activity in acromegaly. Consensus guidelines from the Endocrine Society (2014) recommend a normal (age/sex-adjusted) IGF-1 in combination with a suppressed random GH<1 μg/l for biochemical remission. However, these results are discordant in some patients. The clinical significance of the IGF-1/GH dichotomy in the follow-up of these patients is unclear and...

ea0056gp4 | Acromegaly | ECE2018

Efficacy and safety of switching to pasireotide LAR monotherapy or in combination with pegvisomant in acromegaly patients controlled with combination therapy of somatostatin analogues and pegvisomant (PAPE study): a prospective, open-label 48 week study

Coopmans Eva C , Muhammad Ammar , Janssen Joseph AMJL , van der Lely Aart J , Neggers Sebastian JCMM

Background: In the core phase of the PAPE study until 24 weeks we have shown that switching to pasireotide LAR (PAS-LAR) in well-controlled acromegaly patients receiving combination therapy of somatostatin analogues and pegvisomant (PEGV), normalizes IGF1 levels in the majority of patients. PAS-LAR induced a significant PEGV sparing effect, but this was at the expense of a higher incidence of diabetes. This extension study until 48-weeks assesses the efficacy, safety and quali...

ea0056gp5 | Acromegaly | ECE2018

The importance of MEN1 gene variants in AIP mutation negative FIPA patients

Yarman Sema , Tuncer Feyza Nur , Serbest Esin , Ogret Yeliz

Introduction: Pituitary adenomas (PAs) that occur in a familial setting account for no more than 5%, which can be part of familial tumor syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1) and type 4 (MEN4), Carney Complex (CNC) or Familial Isolated Pituitary Adenoma (FIPA). The presence of two or more cases of PAs without MEN1 or CNC characteristics in the same family, enable FIPA diagnosis. Heterozygous germline inactivating mutations in the aryl hydrocarbon rec...

ea0056gp6 | Acromegaly | ECE2018

IGF-I response to pasireotide LAR treatment in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

Muhammad Ammar , Coopmans Eva , Gatto Federico , Franck Sanne , Janssen Joseph , van der Lelij Aart Jan , Hofland Leo , Neggers Sebastian

Background: The response to first-generation long-acting somatostatin analogues (LA-SSA) treatment in acromegaly depends on the expression of the somatostatin receptor (SSTR) subtypes. In contrast to octreotide and lanreotide which preferentially bind to SSTR2, pasireotide targets multiple SSTRs, with the highest binding affinity for SSTR5. It has previously been suggested that SSTR5 expression could predict the response to pasireotide LAR (PAS-LAR) treatment in acromegaly.</p...

ea0056gp7 | Acromegaly | ECE2018

Familial cancer clustering in patients with pituitary adenoma

Djurdjevic Sandra Pekic , Soldatovic Ivan , Doknic Mirjana , Miljic Dragana , Stojanovic Marko , Petakov Milan , Popovic Vera

Objective: People are at higher risk for malignancy as they get older or have a strong family history of cancer.Aim: To collect family history of cancer in a large cohort of patients with pituitary adenomas (PA) in Outpatient clinic from years 2005–2017.Results: Overall 46% of 1100 patients with PA had a family member affected with cancer. Breast cancer in family members was reported in 15.3% of patients with prolactinomas whi...

ea0056gp8 | Acromegaly | ECE2018

ACRONIS, a European observational study in patients with uncontrolled acromegaly who are being treated with long acting pasireotide: first interim analysis

Schofl Christof , Colao Annamaria , Neggers SJCMM , Feldt-Rasmussen Ulla , Moreno Eva Maria Venegas , Enderle Gesine , Mesenska Daniela , Andry Philippe , Tabarin Antoine

Acromegaly is a morbid condition mainly caused by overproduction of growth-hormone (GH) from a pituitary adenoma leading to excessive growth. Normalisation of insulin-like growth factor-1 (IGF1) is an important goal for the treatment of acromegaly. The second-generation somatostatin analog (SSA) long acting pasireotide (la-PAS) has recently been introduced for the management of patients uncontrolled by first-generation SSA. The ACRONIS study (CSOM230CIC05) will provide real-wo...

ea0056gp9 | Acromegaly | ECE2018

Pregnancy and acromegaly – clinical outcomes from the Irish Pituitary Network

Hannon Anne Marie , O'Shea Triona , Dineen Rosemary , Khattak Aftab , O'Halloran Domhnall , Hunter Steven , Sherlock Mark , Thompson Chris

Acromegaly is a rare disease characterised by excessive Growth hormone (GH) production from a pituitary adenoma. Subfertility is common in acromegaly and has various aetiologies, therefore pregnancy in acromegaly is rare. We present a case series of 19 pregnancies in 13 women with acromegaly from the newly formed Irish National Pituitary Registry. Twelve women had pituitary macroadenomas, one woman had a microadenoma. The age of the women ranged from 28 to 40 years with a medi...

ea0056gp10 | Acromegaly | ECE2018

Human growth hormone (GH) isoforms during oral glucose tolerance test in patients with acromegaly and in healthy subjects

Ulmer Esther , Schilbach Katharina , Haenelt Michael , Nicolay Shiva Sophia , Schwerdt Laura , Schweizer Junia Ribeiro de Oliveira Longo , Bartel Christopher , Schopohl Jochen , Strasburger Christian , Wu Zida , Bidlingmaier Martin

GH consists of various molecular isoforms. Most abundant is 22 kDa-GH (80–90% of total GH), followed by 20 kDa-GH (5–15% of total GH). The biological significance of 20 kDa-GH remains unclear, but its effects appear comparable to those of 22 kDa-GH. Acromegaly is characterized by chronic GH excess. Data on GH isoforms in acromegaly are scarce, but an increased 20 kDa-/22 kDa-GH-ratio (20k-ratio) has been described. Our aims were to compare the 20k-ratio in a larger c...

ea0056gp11 | Acromegaly | ECE2018

Observational, multicentre study to evaluate the effectiveness in routine clinical practice of Lanreotide Autogel 120 mg at extended dosing intervals (>4 weeks) for the treatment of acromegaly: SOMACROL study

Escola Cristina Alvarez , Fajardo Carmen , Marazuela Monica , Carballido Fernando Cordido , Venegas Eva Maria , Velasco Pedro de Pablos , Maroto Gonzalo Piedrola , Marquez Ma del Pilar Olvera , de Paz Isabel Pavon , Carvalho Davide , Romero Carme , De la Cruz Guillermo , Bernabeu Ignacio

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...

ea0056gp12 | Acromegaly | ECE2018

Cumulative effects of growth hormone and insulin-like growth factor-1 exposure on cardiovascular, cerebrovascular and metabolic co-morbidities in acromegaly patients

Seejore Khyatisha , Kyriakakis Nikolaos , Giannoudi Marilena , Lynch Julie , Orme Steve M , Barth Julian H , Murray Robert D

Background: Acromegaly is characterised by growth hormone (GH) and insulin-like growth factor (IGF-1) hypersecretion. The disease is associated with increased cardiovascular, cerebrovascular and metabolic co-morbidities, resulting in excess mortality. A target GH <1 μg/l and normalised IGF-1 values correlate with mortality risk reduction. However, there is lack of consensus over which biomarker, GH or IGF-1, better predicts increased morbidity and/ or mortality.<p...